Georgia State University

ScholarWorks @ Georgia State University
Biology Dissertations

Department of Biology

12-14-2017

Regulation of Nontypeable Haemophilus Influenzae-Induced
Inflammation in Upper Respiratory Tract
Ashley Bohn
aoneill2

Follow this and additional works at: https://scholarworks.gsu.edu/biology_diss

Recommended Citation
Bohn, Ashley, "Regulation of Nontypeable Haemophilus Influenzae-Induced Inflammation in Upper
Respiratory Tract." Dissertation, Georgia State University, 2017.
doi: https://doi.org/10.57709/11097528

This Dissertation is brought to you for free and open access by the Department of Biology at ScholarWorks @
Georgia State University. It has been accepted for inclusion in Biology Dissertations by an authorized administrator
of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.

REGULATION OF NONTYPEABLE HAEMOPHILUS INFLUENZAE-INDUCED
INFLAMMATION IN UPPER RESPIRATORY TRACT

by

ASHLEY O. BOHN
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ABSTRACT

Otitis media (OM) and chronic lung diseases, such as chronic obstructive pulmonary
disease (COPD), are leading causes of antibiotic prescriptions across the globe and of serious
economic concern regarding rising healthcare costs in the U.S. These conditions affect billions of
people globally and cost billions in healthcare dollars annually as well. An in depth understanding
of these disease processes will lead to more effective therapies and reduced healthcare costs
overall. Nontypeable Haemophilus influenzae (NTHi) is a major pathogen associated with OM
and COPD, which are both characterized by inflammation and mucous production at the site of
infection. Mucous is part of the innate immune defenses against infection, and like other innate
defenses, mucous production must be tightly regulated across all mucosal tissues to avoid

deleterious effects and spread of infection. In this dissertation, we show that mice deficient in RIP2 have reduced NTHi burden in the middle ear after infection through the tympanic membrane and
mice deficient in NLRP3 have prolonged infection with NTHi. Our data suggest a role for RIP-2
in establishing NTHi infection within the middle ear. We also investigate the role of RIP-2 in
NTHi infection in vitro and in vivo. We show that RIP-2 is a negative regulator of MUC5AC, a
key mucin produced in the upper respiratory tract, whereas c-Jun N-terminal kinase (JNK) is a
positive regulator of MUC5AC. Our studies provide evidence that RIP-2 plays a novel role in
controlling mucous production in upper respiratory tract. Together, these data suggest that RIP-2
may be a potential therapeutic target to control mucous production and NTHi infection in mucosal
tissues.

INDEX WORDS: Otitis Media, Airway disease, Chronic Obstructive Pulmonary Disease,
Inflammation, Epithelial cells, Nontypeable Haemophilus influenzae, RIP-2, Negative
regulator, JNK
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INTRODUCTION

2

1.1 Innate Defenses and Inflammation

3

In any infection, tight regulation of innate inflammatory pathways is imperative to fight off
pathogenic invaders while avoiding tissue damage. Pathogen recognition receptors (PRRs)
recognize pathogen associated molecular patterns (PAMPs), such bacterial cell wall
components, and initiate cell-signaling cascades to mount an inflammatory response. Heat,
redness, and swelling are some of the classical hallmarks of inflammation and are caused, in
part by, release of cytokines and infiltration of leukocytes to the affected area. These
inflammatory processes are essential in the host’s ability to clear infection. However,
exacerbated inflammation can be detrimental to the host, causing tissue damage and even
spread of the infection.
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5

Mucosal barriers in the upper respiratory tract, including the middle ear, typically aide in
trapping and clearance of infectious agents as a protective mechanism for the host [1]. Mucins
are a major component of mucous in these regions. Mucins are a family of high molecular
weight glycoproteins secreted by goblet cells in mucosal tissues. There are more than 20
known mucins, twelve of which have been found in the respiratory tract [2]. Mucin-5AC
(MUC5AC) is known to be one of the major mucins produced during respiratory infection
and otitis media (OM). While appropriate mucous production is protective for the host,
previous findings have shown mucous overproduction can be deleterious [1-4]. In fact, thick
mucous and neutrophil nets can create a biofilm-like environment for nontypeable
Haemophilus influenzae (NTHi), one of the major bacterial pathogens of OM and chronic
lung diseases, such as chronic obstructive pulmonary disease (COPD). Thickened mucous and
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overproduction of MUC5AC can lead to persistent, chronic infections or can worsen acute
injury [1, 5]. Therefore, like inflammation, mucous production must be tightly controlled.
6
7

1.2 Respiratory Infection in Mucosal Tissues

8

Inflammation in the respiratory tract due to infection is included in such diagnoses as COPD
and OM. COPD is the third leading cause of death in the U.S. with numbers rising each year.
Hassett et al. reported the annual number of Americans affected by COPD in 2014 at over 14
million [6]. COPD is defined as any combination of pulmonary diseases, such as pulmonary
emphysema and chronic bronchitis.

9
10 Otitis Media (OM) is one of the most common pediatric infectious diseases in humans
accounting for over 20 million physician visits and costing the U.S. upwards of 5 billion
dollars annually [7, 8]. OM is characterized by inflammation in the middle ear cavity with or
without effusion, with the most severe infections presenting with the latter. COPD and OM
are most often preceded by a primary upper respiratory viral infection, which allows
commensal bacterial species colonizing the nasopharyngeal and respiratory tracts to become
opportunistic pathogens. Nontypeable Haemophilus influenzae (NTHi) is one of the most
common bacterial pathogens associated with COPD and OM, and currently, the standard
treatment for both diseases is systemically administered broad-spectrum antibiotics. Surgical
intervention is also frequently utilized in OM cases by placing tubes to aid in drainage of the
middle ear cavity in children. This commonplace surgical intervention and frequent use of
antibiotics warrants concern for the development of drug-resistant strains of bacteria as well
as the rising healthcare costs associated with these mucosal ailments. Therefore, more
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innovative and effective treatment options are urgently needed for the treatment of OM in
pediatric patients and COPD in adults.
11
12 1.3 Nontypeable Haemophilus influenzae (NTHi)
13 NTHi strains are known to cause OM in children and exacerbate COPD in adults [9]. Hi
species are gram-negative coccobacilli and are serotyped based on the polysaccharide antigen
in their capsules [10]. The unencapsulated Hi strains are designated nontypeable, because they
do not produce a positive serum serotype [11]. NTHi has been shown in previous studies to
target epithelial cells of the upper respiratory system and affect mucociliary clearance in these
regions via dysregulation of cell signaling pathways [12]. Persistent inflammation has also
been noted in NTHi infections [11]. NTHi infections are becoming more commonplace with
the widespread use of the conjugate vaccines for Haemophilus influenzae serotype B (Hib)
and pneumococcal vaccines [7, 11, 13]. In fact, recent studies indicate invasive species of Hib
have been eradicated in countries that use the vaccine and NTHi is now the most common
commensal Hi strain found in both children and adults [13]. Further research is needed to fully
understand the molecular mechanisms behind exacerbated and prolonged inflammation in
NTHi infections.
14
15

1.4 NLRP3 Inflammasome

16 Inflammasomes are multimeric cytoplasmic protein complexes that are able to sense a diverse
network of cellular stress signals, and traditionally, do not sense pathogen associated
molecular patterns (PAMPs) directly [14]. The NLR family pyrin domain containing 3
(NLRP3) inflammasome contains NLRP3, an adaptor protein, apoptosis-associated speck-like
protein (ASC), and the effector cysteine protease, caspase-1 [14]. NLRP3 inflammasome is
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responsible for cleavage of two critical inflammatory signaling molecules, IL-1β and IL-18,
into their active forms via autolytic cleavage of pro-caspase-1. NLRP3 inflammasome also
regulates important tissue repair processes, such as pyroptosis [15]. IL-1β and IL-18 can
induce a variety of pro-inflammatory responses to combat infection, such as cell proliferation,
recruitment of leukocytes to the site of infection, as well as activation and polarization of Tcell responses [16]. NLRP3 inflammasome is essential for optimal nuclear factor-κB (NF-κB)
activation and has been shown to be vital in clearing numerous types of pathogens, including
NTHi [17, 18]. In fact, mice defective in functional inflammasome complexes show increased
middle ear inflammation and reduced ability to clear NTHi in an OM model [19, 20].
17
18 The mechanisms underlying NLRP3 inflammasome activation are still being heavily

researched, and kinase involvement in NLRP3 inflammasome activation has only recently
been demonstrated [21]. Numerous possible phosphorylation sites on ASC have been
identified [21] indicating several kinases may be involved in inflammasome activation. It is
imperative to understand the mechanisms by which the NLRP3 inflammasome is activated as
novel therapeutic targets may be used to control inflammation during the infection process.
19

20 1.5 Receptor Interacting Protein (RIP)-2
21 RIP-2 plays a key role in NF-κB activation, and previous studies have shown that RIP-2 may
be involved in regulating the NLRP3 inflammasome [22, 23]. Nucleotide-binding
oligomerization domain 1 and 2 (NOD1 and NOD2) are cytosolic receptors upstream of the
NLRP3 inflammasome that detect bacterial peptidoglycans, most notably muramyl dipeptide
(MDP) from the cell walls of bacteria [24]. Upon NOD1/2 detection of PAMPs, they recruit
and interact with RIP-2 via their CARD domains [25]. RIP-2 is a dual-specificity kinase
4

5

downstream

of

NOD1/2,

which

undergoes

autophosphorylation

and

subsequent

polyubiquitination to drive NF-κB transcription of inflammatory cytokines and chemokines
[24], including NLRP3 for inflammasome formation. RIP-2 plays a key role in activation of
multiple inflammatory signaling cascades, including NF-κB and mitogen-activated protein
kinase (MAPK). RIP-2 is not required for NF-κB activation but is an essential signaling
adaptor, and previous studies have shown NF-κB activation is sub-optimal in its absence [26].
22
23 Interestingly, a recent study showed two kinases are able to modulate phosphorylation of ASC

in inflammasome complexes and identified numerous residues as possible phosphorylation
sites [29]. RIP-2 has not yet been fully investigated as a possible activator of the
inflammasome, though RIP-2 has been shown to interact with components of the
inflammasome during early inflammasome formation. Fully understanding the mechanisms
by which inflammasome activation occurs will lead to novel therapeutic targets to control
inflammatory processes downstream of the inflammasome and treat exacerbated
inflammation.
24
25 1.6 Summary
26 Mucosal barriers within the respiratory system, and others such as the gastrointestinal tract,
exist to trap invading pathogens and protect the host from infection. However, if infection
occurs, induction of inflammatory pathways is essential to fight these pathogens. Tight
regulation of inflammation and mucous production is critical for the clearance of bacterial
pathogens and to avoid tissue damage and exacerbated disease states. In NTHi infections,
exacerbated and prolonged inflammation is often seen at the site of infection. Further research
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is needed to fully understand the mechanisms underlying this exacerbated and prolonged
inflammation in NTHi infections.
27
28 The goal of this dissertation work is to investigate the role of RIP-2 and NLRP3
inflammasome in NTHi clearance and in NTHi-induced mucin MUC5AC expression.
Specific aim one examines the relationship between NLRP3 inflammasome, RIP-2, and NTHi
bacterial clearance. This aim will be addressed by investigating 1) if NLRP3 deficient mice
have prolonged presence of NTHi in the middle ear cavity compared to RIP-2 deficient mice
or WT counterparts, 2) if NLRP3 gene expression is inducible by NTHi in vitro. Specific aim
two investigates the role of RIP-2 as a negative regulator of NTHi-induced MUC5AC gene
expression. This aim will be addressed by 1) determining if NTHi induces RIP-2 expression
in vitro and in vivo, 2) if RIP-2 acts as a negative regulator for MUC5AC gene expression in
vitro, 3) if JNK acts as a positive regulator for NTHi-induced MUC5AC expression, 4) if JNK
affects RIP-2 induction
by NTHi, and 5) if Infections
NTHi induces b-defensin in vivo, and 6) if RIP-2
Secondary
Bacterial
deficient mice exhibit increased inflammation in lung infection model.
29
• Epithelial
barrier damage
30

Mucus
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36 Figure 1.1 Mucosal
Barrier at Epithelial Cell Surface
• Disruption
of homeostasis

– Commensal organisms take on a pathogenic role
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102 2. Investigation of NTHi-induced NLRP3
103
104 2.1 Abstract
105 Inflammation is needed to clear pathogens associated with otitis media; a leading cause of
antibiotic prescriptions across the globe and a driving force of rising healthcare costs in the
U.S. However, exacerbated and uncontrolled inflammation can be detrimental. The NLRP3
inflammasome has been shown to be essential in the body’s response to nontypeable
Haemophilus influenzae (NTHi) infection and RIP-2 has been linked to the inflammasome as
a possible activator of the complex. Here we show that mice deficient in RIP-2 exhibited
reduced NTHi burden in the middle ear after infection through the tympanic membrane and

11
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mice deficient in NLRP3 have prolonged infection. Our data suggest an important role for
RIP-2 in establishing NTHi infection within the middle ear.
106
107 2.2 Introduction
108 Tight regulation of inflammation is essential in combating pathogenic invaders. Heat, redness,
and swelling are some of the classical hallmarks of inflammation and are caused by an
elegantly choreographed cascade of inflammatory signals and key pro-inflammatory players,
such as cytokines, chemokines, and leukocytes at the site of infection. These inflammatory
processes are essential in the host’s ability to clear infection. However, exacerbated
inflammation can be detrimental to the host, causing tissue damage and even spread of the
infection.
109
110 Due to the important role NLRP3 plays in mediating pathogen-induced host immune defense
responses, we sought to determine the role of NLRP3 in NTHi-induced infection in a wellestablished mouse model of otitis media (OM). Both the in vitro and in vivo roles of NLRP3
will be determined by using NLRP3 deficient mice and human epithelial cells.
111
112 As previously mentioned, OM is the of the most common pediatric infectious diseases in

humans accounting for millions of physician visits and costing billions of healthcare dollars
annually [1, 2]. NTHi is a part of the upper airway microbiota in healthy individuals and is a
major human pathogen under opportunistic conditions [3, 4]. NTHi is one of the most common
bacterial pathogens associated with OM, and frequent antibiotic prescriptions to combat OM
raise concerns for the development of multi-drug-resistant strains of bacteria as well as the
rising healthcare costs associated with OM due to surgical interventions that are also
12
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commonly utilized in children. Therefore, development of innovative and effective
therapeutic agents is urgently needed for the treatment of OM in pediatric patients.
113

114 Inflammasomes are multimeric cytoplasmic protein complexes which are able to sense a
diverse network of cellular stress signals and are responsible for cleavage of two critical
inflammatory signaling molecules, IL-1β and IL-18, into their active forms [5]. The NLRP3
inflammasome contains NLRP3, an adaptor protein, apoptosis-associated speck-like protein
(ASC), and the effector cysteine protease, caspase-1 [5]. NLRP3 inflammasome is essential
for optimal NF-κB activation and has been shown to be vital in clearing numerous types of
pathogens, including NTHi [6, 7]. In fact, mice defective in functional inflammasome
complexes show increased middle ear inflammation and reduced ability to clear NTHi in an
OM model [8, 9].
115
116 The mechanisms behind NLRP3 inflammasome activation are still being elucidated, and
kinase involvement in NLRP3 inflammasome activation has only recently been demonstrated.
Phosphorylation of Tyr144 in mouse ASC has been established and was required for
inflammasome activation. Phosphorylation of Tyr144 was blocked by inhibition of SYK and
JNK kinases [10]. Additionally, numerous possible phosphorylation sites on ASC have been
identified [10] indicating additional kinases may be involved in inflammasome activation. It
is imperative to understand the mechanisms by which the NLRP3 inflammasome is activated
as novel therapeutic targets may be used to control inflammation during the infection process.
117
118 RIP-2 is a key adaptor molecule and dual-specificity kinase involved in the activation and
regulation of critical cell signaling pathways. Upon NOD1/2 detection of PAMPs in the
13
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cytosol, they recruit and interact with RIP-2 via CARD domains [11]. RIP-2 is a dualspecificity kinase downstream of NOD1/2, which undergoes autophosphorylation and
subsequent polyubiquitination to drive NF-κB transcription of inflammatory cytokines and
chemokines [12], including NLRP3 for inflammasome formation.
119
120 Conflicting reports exist on the involvement of RIP-2 within the NLRP3 inflammasome. RIP2 has been shown to interact with pro-caspase-1 to promote cleavage of pro-IL-1β [13];
however, in another published report, RIP-2 was found to be a negative regulator of the
NLRP3 inflammasome during viral infection, and no difference in inflammasome activation
was reported in Listeria infection in the same study [14]. Additionally, pro-caspase-1 has been
shown to cleave RIP-2, which inhibited NF-κB activation [15]; thus, the involvement of RIP2 in the inflammasome is still not well understood.
121
122 Interestingly, a recent study showed the kinases, SYK and JNK, are able to modulate
phosphorylation of ASC in NLRP3 and AIM2 inflammasome complexes and identified
numerous tyrosine, serine, and threonine residues as possible phosphorylation sites [16]. RIP2 is known to autophosphorylate for protein stability in the NF-κB pathway but has never been
investigated as a possible activator of the inflammasome via phosphorylation of ASC, though
both RIP-2 and ASC interact with pro-caspase-1 during early inflammasome formation. It is
possible that the kinase activity of RIP-2 phosphorylates ASC to activate the inflammasome
complex upon stimulation with one of its known inducers, such as NTHi. Understanding the
mechanism of inflammasome activation will lead to novel therapeutic targets to increase
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activation of the inflammasome in response to infections as well as identify a novel therapeutic
target to control inflammatory processes downstream of the inflammasome.
123
124
125
126
127
128
129 2.3 Materials and Methods
130
131 2.3.1 Bacterial strains and culture conditions
132 Clinical isolates of NTHi 12 and bioluminescent NTHi 1885 MEE/pKMLN-1 were used in
this study. Bioluminescent NTHi 1885 MEE/pKMLN-1 was kindly provided by Dr. Lauren
O. Bakaletz [17]. NTHi were grown as previously described [18-22]. For in vitro experiments,
NTHi was resuspended in PBS and used at a multiplicity of infection (MOI) of 50. For in vivo
experiments, NTHi was resuspended in isotonic saline and used at a concentration of 1 x 107
CFU per mouse.
133
134 2.3.2 Cell culture
135 Cell culture protocols were previously described [18-26]. All media described below were
supplemented with 10% by volume FBS (Sigma-Aldrich) and Pen/Strep (100 U/ml penicillin
and 0.1 mg/ml streptomycin; Life Technologies). Human middle ear epithelial HMEEC-1
cells were maintained in DMEM (Cellgro) supplemented with BEGM SingleQuots (Lonza).
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Human bronchial epithelial cells BEAS-2B cells (ATCC) were maintained in RPMI 1640
medium (Gibco). All cells were cultured at 37°C in 5% CO2.
136
137 2.3.3 Real-time quantitative RT-PCR analysis
138 Total RNA extraction and RT-qPCR were performed as previously described [18-26]. The
relative quantities of mRNAs were determined by using the comparative Ct method and were
normalized by using human cyclophilin for in vitro or mouse glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) for in vivo as endogenous controls and primer sequences for
cyclophilin and GAPDH are previously described [27].The primer sequences of human
NLRP3 and mouse NLRP3 are as follows: human NLRP3 (Forward: 5’-TCT CAT GGA TTG
GTG AAC AGC-3’, and Reverse: 5’-GGT CCC CCA GAG AAT TGT CA-3); mouse NLRP3 (Forward
5’-CCT TGG ACC AGG TCC AGT GT-3’ and Reverse 5’-AGG CAG CAG TTC ACC AGT
CT-3’).
139
140 2.3.4 Mice and animal experiments
141 C57BL/6, NLRP3-/-, and RIP-2-/- mice (7–8 wk old) were available from the Jackson
Laboratory. Anesthetized mice were inoculated transtympanically or intratracheally with
NTHi at a concentration of 1 × 107 CFU per mouse or saline as control. The inoculated mice
were anesthetized using isoflurane gas anesthesia at the time points indicated post inoculation
for in vivo imaging using In vivo Imaging System (Perkin Elmer) and Live Image software.
Eardrums of mice were inspected for signs of middle ear inflammation. All animal
experiments were approved by the Institutional Animal Care and Use Committee at Georgia
State University.
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142
143 2.3.5 Statistical analyses
144 All experiments were repeated in at least three independent experiments. Data are shown as
mean ± SD of n determinations. Statistical analysis was assessed with two-tailed unpaired
Student t-test; p < 0.05 was considered statistically significant.
145
146 2.4 Results and Discussion
147
148 2.4.1 Figure 1. Bacterial Clearance of NTHi in vivo.
149 Inflammasomes are able to sense a diverse network of cellular stress signals. Specifically,
NLRP3 inflammasome is responsible for cleavage of two critical inflammatory signaling
molecules, IL-1β and IL-18, and thus, is needed for a robust inflammatory response against
invading pathogens. NLRP3 inflammasome is also essential for optimal NF-κB activation and
has been shown to be vital in clearing numerous pathogens, including NTHi [6, 7]. RIP-2
also plays a key role in NF-κB activation. For these reasons, we anticipated both NLRP3-/and RIP-2-/- mice will exhibit deficiencies in clearing NTHi infection. Upon infection of
bioluminescent NTHi 1885 MEE/pKMLN-1 into the middle ear cavity of C57BL/6, NLRP3/-

, and RIP2-/- mice via transtympanic membrane injection, mice were imaged using In Vivo

Imaging System (IVIS).
150
151 Interestingly, NLRP3-/- mice showed presence of NTHi at 24 h post infection, while RIP-2-/mice showed clearance of NTHi infection between 9-12 h post infection, which was similar
to wild type mice. These data indicate possibly RIP-2-/- mice are more efficient at clearing
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NTHi infection due to some modulation of cell signaling or inflammatory pathways or,
alternatively, NTHi is not able to remain adhesive to the epithelial surfaces in the middle ear
cavity of RIP-2-/- mice to establish NTHi infection in this region. Previous reports show RIP2 interacts with TRIP6 to potentiate downstream signaling of NF-kB and MAPKs [9], and
depletion of TRIP6 has been shown to affect actin cytoskeletal rearrangements in A431 and
A549 cell lines [10]. Additionally, both NOD2 and RIP-2 knock out mice showed reduced
levels of cellular adhesion molecules ICAM-1 and VCAM-1 upon stimulation with E. coli to
the lungs [11]. Interestingly, NTHi has been shown to adhere to ICAM-1 in respiratory
epithelia and further upregulate it during infection [12]. It’s possible cytoskeletal
rearrangements or altered expression of cellular adhesion molecules impairs NTHi adhesion
on the surface of epithelial cells in the middle ear. While the direct relationship between RIP2 and cytoskeletal rearrangement or the down regulation of cell adhesion molecules effect on
bacterial adhesion to respiratory epithelial cells has not been examined, these items may be
worth looking into in future studies.
152
153 We next sought to determine if RIP-2 could be a therapeutic target to promote clearance of
NTHi; however, current available RIP-2 kinase inhibitors did not show specificity for RIP-2
activity in our models. Thus, development of highly specific inhibitors is needed in the future
to fully evaluate the therapeutic potential of inhibiting RIP-2 in treating otitis media. (Please
see chapter 3 of this dissertation for additional work in RIP2-/- mice).
154
155 2.4.2 Figure 2. NTHi induced NLRP3 gene expression in vitro.
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156 Because induction of host innate immune regulators is known to play a key role in mediating
inducible host defense response, we next sought to determine if NLRP3 is also inducible in
our models. As shown in Figure 2A and 2B, NTHi markedly induced NLRP3 gene expression
in vitro in human epithelial cells. Together our data indicate an important role of NLRP3 as
well as RIP-2 in NTHi-induced host immune defense responses. Since RIP-2 is known as the
key regulator of NLRP3, we thus sought to further investigate the role of RIP-2 in NTHi
infections in Chapter 3.
157
158
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Figure 1. Bacterial clearance of NTHi.
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161 Figure 1. Bacterial clearance of NTHi in vivo.
162 Bioluminescent NTHi 1885 MEE/pKMLN-1 was inoculated into the middle ear cavity of
C57BL/6, NLRP3-/-, and RIP-2-/- mice via transtympanic membrane injection at a dose of 1 x
107 CFU. Mice were anesthetized and imaged using In Vivo Imaging System (IVIS). NLRP3/-

mice show presence of NTHi at 24 h post infection. RIP-2-/- mice show clearance NTHi

infection between 9-12 h post infection.
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Figure 2. NTHi-induced NLRP3 gene expression in vitro.
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173 Figure 2. NTHi-induced NLRP3 gene expression in vitro.
174 NTHi induced NLRP3 expression at mRNA level in vitro (A and B). HMEEC-1 (A) and
BEAS-2B (B) cells were stimulated with NTHi lysate for 5h, and NLRP3 mRNA expression
analyzed by q-PCR. Data are means ± SD (n = 3); *P<0.05.
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248 Abstract
249

Appropriate production of mucous plays a critical role in host innate mucosal defenses
against infection. However, if uncontrolled, excessive mucous may be detrimental to the host.
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Mucous production thus must be tightly regulated. In the present study, we investigate the role
of RIP-2 in regulating nontypeable Haemophilus influenzae (NTHi)-induced up-regulation of
mucin MUC5AC expression. We show that RIP-2 is a negative regulator of MUC5AC,
whereas MAP kinase JNK acts as a positive regulator for MUC5AC induction by NTHi. Our
studies unveil a novel role for RIP-2 in controlling mucous production in upper respiratory
disease and may shed light on the identification of new therapeutic targets.
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260 Introduction
261

Mucosal barriers in the upper respiratory tract, including the middle ear, typically aide in
trapping and clearance of infectious agents as a protective mechanism for the host [1]. Mucins
are a major component of mucous in these regions. Mucins are a family of high molecular
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weight glycoproteins secreted by goblet cells in mucosal tissues. There are more than 20
known mucins, twelve of which have been found in the respiratory tract [2]. Mucin 5AC
(MUC5AC) is known to be one of the major mucins produced during upper respiratory
infections, including otitis media (OM). While appropriate mucous production is protective
for the host, excessive mucous production can be deleterious [1-4]. In fact, thick mucous and
neutrophil nets can create a biofilm-like environment for nontypeable Haemophilus influenzae
(NTHi), one of the major bacterial pathogens of OM and chronic obstructive pulmonary
disease (COPD). Overproduction of mucin MUC5AC can lead to persistent, chronic
infections or can worsen acute tissue injury [1, 5]. Therefore, like inflammation, mucous
production must be tightly controlled.
262
263

NTHi-caused upper respiratory infections, including COPD and OM, remain major health
problems worldwide. COPD is the third leading cause of death in the U.S. with numbers rising
each year. Hassett et al. reported the annual number of Americans affected by COPD in 2014
at over 14 million [6]. OM is the most common pediatric infectious disease in humans
accounting for over 20 million physician visits and costing the U.S. upwards of 5 billion
dollars annually [7, 8]. OM is characterized by mucous overproduction and inflammation in
the middle ear cavity due to infection. Pediatric patients are highly susceptible to OM
pathogens due to the shortened length of the Eustachian tube during development [7].
Currently, the standard treatment for both COPD and OM is systemically administered broadspectrum antibiotics, which, leads to increased antibiotic resistance. Surgical intervention is
also frequently utilized in pediatric OM patients by placing tubes to aid in drainage of the
middle ear cavity. This commonplace surgical intervention and frequent use of antibiotics
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warrants concern for the development of drug-resistant strains of bacteria as well as the rising
healthcare costs associated with both inflammatory diseases. Therefore, development of nonantibiotic therapeutic strategies is urgently needed based on a full understanding of the
molecular pathogenesis of these inflammatory diseases.
264
265

Receptor interacting protein-2 (RIP-2) plays a key role in activation and regulation of
multiple inflammatory signaling cascades, including nuclear factor-κB (NF-κB) and mitogenactivated protein kinase (MAPK). Nucleotide-binding oligomerization domain 2 (NOD2) is a
cytosolic receptor that detects bacterial peptidoglycans and other inflammatory stimuli [9].
Upon NOD2 detection of pathogen-associated molecular patterns (PAMPs), RIP-2 is recruited
and interacts via CARD-CARD interactions. RIP-2 is a dual-specificity kinase downstream
of

NOD-like

receptors,

which

undergoes

autophosphorylation

and

subsequent

polyubiquitination to drive transcription of inflammatory cytokines and chemokines [9]. RIP2 is an essential signaling adaptor, and previous studies have shown NF-κB activation is suboptimal in its absence [10]. Previous studies have also shown that RIP-2 acts as an important
adaptor molecule for ovalbumin-induced lung inflammation [11]. However, the role of RIP-2
in bacteria-induced expression of mucin MUC5AC, a major contributor of OM and COPD
pathology, remains largely unknown.
266
267

In the present study, we sought to investigate the role of RIP-2 in NTHi-induced MUC5AC
gene expression. Here we show that NTHi induces RIP-2 expression at mRNA and protein
levels, and RIP-2 is a negative regulator of MUC5AC expression, whereas c-Jun N-terminal
kinase (JNK) is a positive regulator for MUC5AC induction. Thus, our study provides the
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direct evidence for the first time of the negative regulation of MUC5AC induction by NTHi
via RIP-2 signaling pathway and may lead to the development of new therapeutic strategies
for suppressing MUC5AC overproduction.
268

269 Materials and Methods
270
271 Reagents and antibodies
272

SP600125 was purchased from Calbiochem. Antibodies against β-actin (sc-8432), αtubulin (sc-69969) and total JNK1/2 (sc-7345) were purchased from Santa Cruz
Biotechnology. Antibodies for phospho-JNK1/2 (#9251), anti-rabbit HRP-linked antibody
(#7074) and anti-mouse HRP-linked antibody (#7076) were purchased from Cell Signaling.
Antibody against RIP-2 (ab8428) was purchased from Abcam.

273
274 Bacterial strains and culture conditions
275

Clinical isolate of NTHi 12 was used in this study. NTHi were grown as previously
described [12-16]. For in vitro experiments, NTHi was resuspended in PBS and used at a
multiplicity of infection (MOI) of 50. For in vivo experiments, NTHi was resuspended in
isotonic saline and used at a concentration of 1 x 107 CFU per mouse.

276
277 Cell culture
278

Cell culture protocols were previously described [2-4, 12-17]. All media described below
were supplemented with 10% by volume FBS (Sigma-Aldrich) and Pen/Strep (100 U/ml
penicillin and 0.1 mg/ml streptomycin; Life Technologies). Human middle ear epithelial
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HMEEC-1 cells were maintained in DMEM (Cellgro) supplemented with BEGM SingleQuots
(Lonza). Human bronchial epithelial cells BEAS-2B cells (ATCC) were maintained in RPMI
1640 medium (Gibco). All cells were cultured at 37°C in 5% CO2.
279
280 Real-time quantitative RT-PCR analysis
281

Total RNA extraction and RT-qPCR were performed as previously described [2-4, 12-17].
The relative quantities of mRNAs were determined by using the comparative Ct method and
were normalized by using human cyclophilin for in vitro or mouse glyceraldehyde-3poosphate dehydrogenase (GAPDH) for in vivo as endogenous controls. The primer sequences
of human MUC5AC, mouse MUC5AC, human cyclophilin and mouse GAPDH were
described previously [2, 18]. The primer sequences of RIP-2 are as follows: human RIP-2
(Forward 5’-CAA GCA CGA TAT ATA TAG CTA TGC AG-3’ and Reverse 5’-GCA AAG
GAT TGG TGA CAT CCT C-3’); mouse RIP-2 (Forward 5’-GGG AAT TTG CAA TGA
GCC TG-3’ and Reverse 5’-GCA GGA TGC GGA ATC TCA AT-3’).

282
283
284
285 Plasmids and transfections
286

RIP-2 siRNA (SR305775) and control siRNA (SR30004) were purchased from Origene.
All transient transfections were performed using Lipofectamine RNAiMAX (Thermo Fisher
Scientific) according to the manufacturers’ instructions. For experiments with inhibitors, the
transfected cells were pretreated with or without chemical inhibitors for 1 h followed by 5 h
of incubation with NTHi.
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287
288 Western blot
289

Western blot procedures were previously described [2-4, 12-17]. Western blots were
performed using whole-cell extracts, separated on 8-10 % SDS-PAGE gels, and transferred to
polyvinylidene difluoride (PVDF) membranes. The membrane was blocked with a solution of
Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) and 5% non-fat dry milk. The
membrane was then incubated in a 1:2,000 dilution of a primary antibody in 5% bovine serum
albumin-TBS-T. After three washes in TBS-T, the membrane was incubated with 1:5,000
dilution of the corresponding secondary antibody in 5% non-fat dry milk-TBS-T. Respective
proteins were visualized by using Amersham ECL Prime Reagent (GE Healthcare Life
Science).

290
291 Mice and animal experiments
292

C57BL/6 and RIP-2-/- mice (7-8 weeks old) were purchased from the Jackson Laboratory.
Anesthetized mice were inoculated with NTHi at a concentration of 1 × 107 CFU per mouse
or saline as control [2]. The inoculated mice were sacrificed at 6 and 12 h post-inoculation.
Eardrums of mice were inspected for signs of middle ear inflammation. Dissected mouse
middle ears were then subjected to total RNA extraction and histologic analyses. All animal
experiments were approved by the Institutional Animal Care and Use Committee at Georgia
State University.

293
294 Histology

32
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295

As previously described [2], formalin-fixed paraffin-embedded mouse middle ear tissues
were sectioned (4 µm), and then stained with hematoxylin and eosin (H&E) to visualize
inflammatory responses and pathological changes in the middle ear. Images of stained cells
and tissue sections were recorded with light microscopy system (Carl Zeiss).

296
297 Statistical analyses
298 All experiments were repeated in at least three independent experiments. Data are shown as
mean ± SD of n determinations. Statistical analysis was assessed with two-tailed unpaired
Student t-test; p < 0.05 was considered statistically significant.
299

300 Results and Discussion
301 NTHi induces RIP-2 in human epithelial cells in vitro and in mouse middle ear in vivo.
302

RIP-2 is a dual specificity kinase known to modulate inflammatory signaling pathways.
Previous studies have shown the role of RIP-2 to be complex in various diseases. For example,
RIP-2 deficient mice were shown to be resistant to developing arthritis and autoimmunemediated cephalomyelitis associated with a multiple sclerosis model [9, 19, 20].
Paradoxically, dysregulation of the NOD2/RIP-2 pathway has been implicated in
dysregulation of cell signaling pathways during viral infection [9, 21]. To investigate the role
of RIP-2 in NTHi-induced mucin expression in our experimental models, we first examined
whether NTHi induces RIP-2 in vitro. We treated human epithelial cells with NTHi and
measured RIP-2 mRNA expression by performing quantitative PCR (Q-PCR) analysis. NTHi
induced RIP-2 expression at mRNA level in human middle ear epithelial HMEEC-1 cells
(Figure 1A) and human bronchial epithelial BEAS-2B cells (Figure 1B). We also confirmed
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a time-dependent induction of RIP-2 at the protein level (Figure 1C). Consistent with in vitro
findings, NTHi-induced RIP-2 mRNA expression was also confirmed in the middle ear of
mice by q-PCR analysis (Figure 1D). Collectively, these results that NTHi induces expression
of RIP-2 in vitro and in vivo.
303
304 RIP-2 acts as a negative regulator for NTHi-induced MUC5AC expression.
305

On the basis that mucous overproduction is a hallmark of NTHi-infections and NTHi
markedly induce RIP-2 expression, we hypothesized that RIP-2 may play a critical role in
regulating mucin production [22]. To determine the role of RIP-2 in MUC5AC induction, we
utilized small interfering RNA (siRNA) specific for RIP-2 in human epithelial cells. We first
evaluated the efficiency of RIP-2 knockdown. As shown in Figure 2A, RIP-2 siRNA
efficiently depleted RIP-2 expression. Next, we evaluated the effect of siRNA RIP-2 on
MUC5AC induction. Interestingly, siRIP-2 markedly enhanced NTHi-induced MUC5AC upregulation in HMEEC-1 cells (Figure 2B). Moreover, we determined if NTHi also induces
effusion in the middle ear of the mouse otitis media models. As shown in Figure 2C, increased
effusion was observed in RIP-2 deficient mice compared with WT control mice as early as 12
hours post-infection. Together, our data indicate that RIP-2 is a negative regulator for NTHiinduced MUC5AC expression.

306
307 JNK acts as a positive regulator for NTHi-induced MUC5AC up-regulation.
308

MAP kinase JNK has been shown to play a critical role in mediating bacteria-induced
inflammatory responses [4, 23]. Thus, we sought to determine the role of JNK in NTHiinduced MUC5AC expression. We first confirmed the activation of JNK by NTHi. NTHi
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induced potent activation of JNK in a time-dependent manner in human epithelial cells
(Figure 3A). We next evaluated the effects of JNK specific inhibitor (SP600125) on NTHiinduced MUC5AC expression. As shown in Figure 3B, inhibition of JNK suppressed NTHiinduced MUC5AC expression, thereby indicating a critical role of JNK as a positive regulator
for NTHi-induced MUC5AC expression. The role of JNK in regulating bacteria-induced host
mucosal immune responses is highly complex and may act differently depending on the
pathogen as well as on the host genes. The positive regulation of MUC5AC expression by
JNK may be due to its role in mediating the activation of the signaling pathways including the
transcription factors leading to the transcriptional up-regulation of MUC5AC expression. We
previously reported that JNK negatively regulates MUC5AC expression via targeting negative
activator protein-1 (AP-1) site in Streptococcus pneumoniae infection [4]. Thus, it is possible
that JNK positively regulates NTHi-induced MUC5AC expression through the AP-1 site in
the promoter region of MUC5AC gene. Future studies are needed to confirm this hypothesis
by using AP-1 site mutants of MUC5AC-Luc luciferase reporter promoter constructs.
309
310 JNK acts as a negative regulator for NTHi-induced RIP-2 expression.
311

Having demonstrating the positive role of JNK in mediating the up-regulation of mucin
MUC5AC by NTHi, we next sought to explore if JNK may also mediate up-regulation of
MUC5AC by suppressing the expression of RIP-2, the negative regulator for NTHi-induced
MUC5AC expression. Interestingly, inhibition of JNK using JNK specific inhibitor enhanced
NTHi-induced expression of RIP-2 (Figure 4). This exciting result provides direct evidence
to unveil the complex molecular mechanism by which JNK mediates NTHi-induced mucin
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MUC5AC expression likely via up-regulation of MUC5AC transcription and also via
inhibition of the induction of negative regulator RIP-2 expression (Figure 5).
312
313

Taken together, our studies bring new insights into the complex regulatory mechanism
underlying bacteria-induced up-regulation of mucous and may be helpful for developing new
therapeutic strategies for suppressing mucous overproduction in upper respiratory infectious
diseases. Future studies are needed for further investigating the precise molecular mechanisms
underlying tight regulation of mucous overproduction.
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Figure 1. NTHi induces RIP-2 expression in vitro and in vivo.
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323 Figure 1. NTHi induces RIP-2 in human epithelial cells in vitro and in vivo.
324

HMEEC-1 (A) and BEAS-2B (B) cells were stimulated with NTHi for 5h, and RIP-2
mRNA expression was analyzed by Q-PCR analysis. (C) Cells were stimulated with NTHi
for various time periods (1, 3, 5, or 7h) and RIP-2 protein expression was analyzed by Western
blot analysis. (D) C57BL/6 mice were transtympanically inoculated with NTHi or control for
6h, and RIP-2 mRNA expression was analyzed by Q-PCR analysis. Data in A-B, D are means
± SD (n = 3); *P<0.05.
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327 Figure 2. RIP-2 acts as a negative regulator for NTHi-induced MUC5AC expression.
328

(A & B) HMEEC-1 cells were transfected with siRNA for RIP-2 or control for 40 h and
were then stimulated with NTHi for 5h and analyzed for RIP-2 (A) and MUC5AC (B) mRNA
expression by Q-PCR analysis. (C) Middle ear tissue sections from C57BL/6 or RIP-2-/- mice
transtympanically inoculated with NTHi (1 x 107 CFU) or control were stained with
hematoxylin and eosin stain, magnification x 200, visualized with Carl Zeiss light microscope.
Scale bar: 20µm. Data in A-B are means ± SD (n = 3); *P<0.05.
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Figure 3. JNK acts as a positive regulator for NTHi-induced MUC5AC up-regulation.
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330 Figure 3. JNK acts as a positive regulator for NTHi-induced MUC5AC expression.
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(A) HMEEC-1 cells were treated with NTHi for indicated time periods, and cell lysates
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were analyzed by Western blot analysis with indicated antibodies. (B) HMEEC-1 cells wereNTHi lysate 1:10, siRN
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Figure 4. JNK acts as a negative regulator for NTHi-induced RIP-2 expression.
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339 Figure 4. JNK acts as a negative regulator for NTHi-induced up-regulation of RIP-2
Expression.
340 HMEEC-1 cells were pretreated with 5 µM JNK inhibitor (SP600125) for 1 h followed by
stimulation with NTHi for 5 h, and RIP-2 mRNA expression was then analyzed by Q-PCR
analysis. Data are means ± SD (n = 3); *P<0.05.
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Figure 5. Schematic model illustrating NTHi-induced MUC5AC is negatively regulated by RIP-2.
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350 Figure 5. A Schematic diagram illustrating that JNK acts as a positive regulator for
NTHi-induced up-regulation of mucin MUC5AC expression. In contrast, RIP-2 acts as
a negative regulator for MUC5AC induction.
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386 3. 5 Appendix A
44

45

387 Figure 6. NTHi-induced b-defensin gene expression in vivo.
388 Defensins are part of the innate defenses against microbial invasion. They constitute a family
of antimicrobial peptides, which interact with the membranes of bacteria based on charge.
Mouse b-defensin 3 is homologous for human b-defensin 2 and has been shown to be present
in respiratory tissues [27].
389
390 Here we examined C57BL/6 and RIP2-/- mice inoculated with NTHi via transtympanic
membrane injection into the middle ear. Mice were sacrificed at 2, 4, and 6 h post inoculation
and b-defensin mRNA expression analyzed by q-PCR. In Figure 6, RIP-2-/- mice showed
eight-fold increase in b-defensin 3 mRNA in the middle ear four hours post inoculation with
NTHi as the WT counterparts (Figure 6). Given the antimicrobial nature of defensins, this
spike in b-defensin 3 might explain the clearance of bioluminescent NTHi in our study (Figure
1.1). Further investigation is needed to fully understand the role of b-defensin in RIP-2-/- mice.
391
392 Primer sequence for mouse b-defensin 3 is as follows: (Forward: 5’-GTC TCC ACC TGC AGC
TTT TAG-3’, and Reverse: 5’-CCA ATC TGA CGA GTG TTG C-3’).
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Figure 6. NTHi-induced β-defensin gene expression in vivo.
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406 Figure 6. NTHi-induced b-defensin gene expression in vivo.
407 C57BL/6 and RIP2-/- mice were inoculated with NTHi at 1 x 107 CFU via transtympanic
membrane injection into the middle ear. Mice were sacrificed at 2, 4, and 6 h post inoculation
and b-defensin mRNA expression analyzed by q-PCR.
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46

47

420 Figure 7. RIP-2 modulates NTHi-induced inflammation in mouse lung.
421 In Figure 7, lung tissue sections from C57BL/6 or RIP-2-/- mice intratracheally inoculated with
NTHi or control were stained with hematoxylin and eosin stain. Interestingly, histology from
lung tissue showed dissimilar results to the histology shown in Figure 3.2 of mouse middle
ear following infection with NTHi. RIP-2-/- mouse lung tissue shows decreased inflammation
following infection with NTHi, while WT counterparts show a robust inflammatory response.
It’s possible the microbiota and resident immune cells in these tissues differ and this may help
to explain the dissimilarities seen in the histology data. Additional studies are needed to fully
understand the differences seen here.
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428 Figure 7. RIP-2 modulates NTHi-induced inflammation in mouse lung.
429
430 Lung tissue sections from C57BL/6 or RIP-2-/- mice intratracheally inoculated with NTHi or
control were stained with hematoxylin and eosin stain, magnification x 100 or x 400,
visualized with Carl Zeiss light microscope.
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439
440 4 Conclusion
441 Otitis media (OM) and chronic lung diseases, such as chronic obstructive pulmonary disease
(COPD), are major sources of concern for rising healthcare costs, development of multi-drug
resistant strains of bacteria through repeated antibiotic prescriptions, as well as the pain and
suffering of patients given these conditions affect billions of people globally. Therefore, it’s
essential to understand the underlying disease processes and identify novel therapeutic targets
to better treat these patients and reduce healthcare costs associated with OM and COPD.
442
443 Nontypeable Haemophilus influenzae (NTHi) is a major pathogen associated with OM and
COPD, which are both characterized by inflammation and mucous production at the site of
infection. NTHi and other Haemophilus strains are present in the normal microbiota of the
upper respiratory tract. However, under opportunistic conditions, such as during or following
a primary viral infection, NTHi can take on a pathogenic role in the respiratory tract. Innate
defenses exist to prevent such infections. Mucosal barriers in the upper respiratory tract,
including the middle ear, typically aide in trapping and clearance of infectious agents as a
protective mechanism for the host [1]. While appropriate mucous production is protective for
the host, previous findings have shown mucous overproduction can be deleterious [1-4],
actually creating niches for bacteria to form biofilms and even spread infection [5].
Additionally, exacerbated and uncontrolled inflammation in these areas can cause irreversible
tissue damage to the host.
444
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445 For these reasons, inflammation and mucous production must be tightly controlled, and as
such, there exist many regulators of inflammatory pathways, which control pro-inflammatory
cytokine and chemokine production as well as mucin expression. RIP-2 is an essential
signaling adaptor protein downstream of the NOD-like receptors, which has previously been
shown to play a key role in NF-κB activation. RIP-2 undergoes autophosphorylation and
subsequent polyubiquitination to drive transcription of inflammatory cytokines and
chemokines [6], including NLRP3 for inflammasome formation. Additionally, RIP-2 plays a
key role in activation and regulation of multiple inflammatory signaling cascades, including
NF-κB and MAPK.
446
447 Inflammasomes are able to sense a diverse network of cellular stress signals. Specifically,
NLRP3 inflammasome is responsible for cleavage of two critical inflammatory signaling
molecules, IL-1β and IL-18, and thus, is needed for a robust inflammatory response against
invading pathogens. NLRP3 inflammasome is also essential for optimal NF-κB activation and
has been shown to be vital in clearing numerous pathogens, including NTHi [7, 8].
448
449 In this dissertation work, we sought to determine the role of RIP-2 and NLRP3 inflammasome
in NTHi clearance and the role of RIP-2 in NTHi-induced MUC5AC expression. Specific aim
one examined the relationship between NLRP3 inflammasome, RIP-2, and NTHi bacterial
clearance. Through this work we examined and showed 1) NLRP3 deficient mice have
prolonged presence of bioluminescent NTHi in the middle ear cavity compared to RIP-2
deficient mice or WT counterparts and 2) NLRP3 gene expression is inducible by NTHi.
Specific aim two investigated the role of RIP-2 as a negative regulator of NTHi-induced
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MUC5AC gene expression. This aim showed 1) NTHi induces RIP-2 expression in vitro and
in vivo both at mRNA and protein levels; 2) RIP-2 acts as a negative regulator for MUC5AC
gene expression; 3) JNK positively regulates NTHi-induced up-regulation of MUC5AC
expression; 4) JNK acts as a negative regulator for NTHi-induced RIP-2 expression, 5) NTHi
caused induction of b-defensin in vivo in RIP-2 knockout mouse; and 6) RIP-2 deficient mice
exhibit increased inflammation in lung infection model.
450
451 We initially sought to investigate the role of RIP-2 in regulating the NLRP3 inflammasome.
However, during our initial investigations, we had two interesting observations. First, we were
unable to attain inducible levels of NLRP3 in vivo in our models, and second, RIP-2-/- mice
showed reduced loads of NTHi following infection with the bioluminescent NTHi 1885
MEE/pKMLN-1 into the middle ear via transtympanic membrane injection. Interestingly,
NLRP3-/- mice showed enhanced presence of NTHi at 24 h post infection, while RIP-2-/- mice
showed clearance of NTHi infection between 9-12 h post infection, which was similar to wild
type mice (Ch 2, Fig 1). These data indicate possibly that RIP-2-/- mice are more efficient at
clearing NTHi infection due to some modulation of cell signaling or inflammatory pathways
or, alternatively, NTHi cells are less adhesive to the epithelial surfaces in the middle ear cavity
of RIP-2-/- mice and therefore, unable to establish infection in the middle ear. As previously
mentioned in chapter 2, depletion of TRIP6 has been shown to affect actin cytoskeletal
rearrangements [10]. Additionally, the cellular adhesion molecule ICAM-1 is down-regulated
in RIP-2 deficient mice [11], and NTHi has been shown to adhere to ICAM-1 in respiratory
epithelia and further upregulate it during infection [12]. While there is currently no direct

51

52

evidence linking RIP-2 and cytoskeletal rearrangement or the down regulation of ICAM-1 to
reduced bacterial adhesion, these items may be worth looking into in future studies.
452
453 We successfully demonstrated that NTHi-induced NLRP3 gene expression in vitro in human
epithelial cells (Ch 2, Fig 2A and 2B); however, we were unable to attain NLRP3 induction
at mRNA levels in vivo after NTHi infection in our models. We next sought to determine if
RIP-2 could be a therapeutic target to promote clearance of NTHi; however, currently
available RIP-2 kinase inhibitors did not show high specificity for RIP-2 activity in our
models. Further evaluation of our data led us to focus our investigation on the role of RIP-2
in NTHi-induced OM (chapter 3).
454
455 In chapter 3, we’ve shown that RIP-2 is inducible by NTHi both in vitro and in vivo at
transcriptional and translational levels, indicating a pro-inflammatory role for RIP-2 in NTHi
infection (Ch 3, Fig 1). Additionally, we showed RIP-2 negatively regulates MUC5AC
expression, whereas JNK acts as a positive regulator of MUC5AC at least in part via inhibition
of NTHi-induced RIP-2 expression (Ch 3, Fig 2 and Fig 3).
456
457 In Chapter 3, Figure 2, middle ear histology data show that RIP-2-/- mice have onset of
inflammatory histopathology at earlier time points than wild-type counterparts following
infection with NTHi. Interestingly, signs of inflammation resolve after 48 hours in RIP-2-/mice while C57BL/6 wild type mice have marked inflammation at similar time points (data
not shown). This suggests a faster inflammatory response, possibly from alterations in sensing
PAMPs or cell signaling pathways, from mice deficient in RIP-2 prevents NTHi from being
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able to successfully infect the middle ear cavity following inoculation through the tympanic
membrane.
458
459 There are several possible explanations for these results, including that NTHi may be less
adhesive to epithelial cells in RIP-2-/- mice as NTHi is known to target ciliated epithelial cells
of the respiratory tract [13]. It’s possible RIP-2 affects cytoskeletal arrangement or expression
of cell surface markers of ciliated cells in the middle ear, and thus, NTHi is impaired in
establishing infection in mice lacking RIP-2. Additional research is needed to provide direct
evidence of these, however. An alternative explanation is there is a fast and robust release of
antimicrobial defenses, such as b-defensin 3. In our study, RIP-2-/- mice showed an eight-fold
increase in b-defensin 3, a homologue of human b-defensin 2, mRNA in the middle ear four
hours post inoculation with NTHi as the WT counterparts (Ch 3, Fig 6). Defensins are a family
of antimicrobial peptides, which might explain the clearance of bioluminescent NTHi in our
study (Ch 2, Fig 1). Further investigation is needed to fully understand the role of b-defensin
in RIP-2-/- mice.
460
461 Together with the data that RIP-2 is a negative regulator for MUC5AC expression (chapter
3), it’s possible that increased mucous production in RIP-2-/- mice allows for faster clearance
of NTHi following infection. Additional studies are needed to fully characterize the role of
mucin in RIP-2-/- mice and/or to possibly develop a specific inhibitor of RIP-2 should the
depletion of RIP-2 prove beneficial in the clearance of pathogens from the middle ear.
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463 In Chapter 3, Figure 7, H&E staining of mouse lung tissue from C57BL/6 and RIP-2-/- mice
show dissimilar results to the histology shown in Figure 2 (Chapter 3) of mouse middle ear
following infection with NTHi. RIP-2-/- mouse lung tissue shows decreased inflammation
following infection with NTHi, while C57BL/6 WT counterparts show a robust inflammatory
response. It’s possible the microbiota and resident immune cells in these tissues differ and
these variances may explain the dissimilarities seen in the histology data.
464
465 RIP-2 has been shown to be a key signaling adaptor in multiple inflammatory signaling
pathways. We showed here that RIP-2 may be a potential therapeutic target to control mucous
production and combat NTHi infection in the middle ear. However, future studies are needed
to fully understand the role of RIP-2 in clearing NTHi in multiple tissues and mucosal systems.
It is also important to investigate if increased mucous production through RIP-2 modulation
of signaling pathways will be beneficial in human patients as any prescribed or over the
counter medication will most likely be given after infection has begun. Still, the role of RIP2 in possibly preventing NTHi from establishing infection in the middle ear is interesting and
warrants further investigation.
466
467 Experimental limitations of this study include lack of a specific inhibitor for RIP-2 and the
inability to attain inducible levels of NLRP3 in our animal models. Addition of a highly
specific RIP-2 inhibitor would allow researchers to explore potential pharmaceutical control
of RIP-2 activity on OM pathology.
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469 Additionally, our infection models utilize acute models of inflammation. To fully understand
the chronic nature of OM and diseases like COPD, a dependable chronic inflammation model
is urgently needed.
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